The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin

Immunology and Cell Biology

Volumn 76, Issue 3, 1998, Pages 270-279

  De Haan, Lolke ^a   Verweij, Willem ^a   Agsteribbe, Etienne ^a   Wilschut, Jan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Adjuvant; Immunization; Toxin; Vaccine

Indexed keywords

CHOLERA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLOGICAL ADJUVANT;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; ESCHERICHIA COLI; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; VIBRIO CHOLERAE;

ADENOSINE DIPHOSPHATE RIBOSE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BACTERIAL TOXINS; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; G(M1) GANGLIOSIDE; HUMANS; IMMUNITY, MUCOSAL; PROTEIN BINDING; VIBRIO CHOLERAE;

ESCHERICHIA COLI; VIBRIO CHOLERAE;

EID: 0031842147     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00745.x     Document Type: Article

References (95)

1. Mestecky J, McGhee JR. Immunoglobulin A (IgA): Molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 1987; 40: 153-245.
2. Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J. Handbook of Mucosal Immunology. San Diego: Academic Press, 1994.
3. Kuper CF, Koornstra PJ, Hameleers DMH et al. The role of nasopharyngeal tissue. Immunol. Today 1992; 13: 219-24.
4. Wu HY, Russell MW. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol. Res. 1997; 16: 187-201.
5. Neutra MR, Pringault E, Kraehenbuhl JP. Antigen sampling across epithelial barriers and induction of mucosal immune responses. Annu. Rev. Immunol. 1996; 14: 275-300.
6. McGhee JR, Mestecky J, Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: From fundamental concepts to Vaccine development. Vaccine 1992; 10: 75-88.
7. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system: I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. Vaccine J. Immunol. 1979; 122: 1892-8.
8. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system: II. Influence of the estrous cycle on B immunoblast migration into genital and intestinal tissues. J. Immunol. 1980; 124: 2536-9.
9. Weiner HL. Oral tolerance. Proc. Natl Acad. Sci. USA 1994; 91: 10762-5.
10. Snider DP. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit. Rev. Immunol. 1995; 15: 317-48.
11. 5 toxins. Curr. Opin. Struct. Biol. 1995; 5: 165-71.
12. Sixma TK, Pronk SE, Kalk KH et al. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 1991; 351: 371-7.
13. M1 pentasaccharide. Protein Sci. 1994; 3: 166-75.
14. Zhang RG, Westbrook ML, Westbrook EM et al. The 2.4Å crystal structure of cholera toxin B subunit pentamer: Choleragenoid. J. Mol. Biol. 1995; 251: 550-62.
15. Zhang RG, Scott DL, Westbrook ML et al. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol. 1995; 251: 563-73.
16. Yamamoto T, Nakazawa T, Miyata T, Kaji A, Yokota T, Evolution and structure of two ADP-ribosylating enterotoxins, Escherichia coli heat-labile toxin and cholera toxin. FEBS Lett. 1984; 169: 241-6.
17. Spangler BD. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol. Rev. 1992; 56: 622-47.
18. Fukuta S, Twiddy EM, Magnani JL, Ginsburg V, Holmes RK. Comparison of the carbohydrate binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LTH-1, LT-1a, and LT-1b. Infect. Immun. 1988; 56: 1748-53.
19. Holmgren J, Fredman P, Lindblad M, Svennerholm AM, Svennerholm L. Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect. Immun. 1982; 38: 424-33.
20. Teneberg S, Hirst TR, Ångstrom J, Karlsson KA. Comparison of cholera toxin and porcine Escherichia coli heat-labile enterotoxin: Identification of a receptor-active non-ganglioside glycolipid for the heat-labile toxin in infant rabbit small intestine. Glycoconj. J. 1994; 11: 533-40.
21. Tsuji T, Watanabe K, Miyama A. Monomer of the B subunit of heat-labile enterotoxin from enterotoxigenic Escherichia coli has little ability to bind to GMI ganglioside compared to its coligenoid. Microbiol. Immunol. 1995; 39: 817-19.
22. Cieplak W, Messer RJ, Konkel ME, Grant CCR. Role of a potential endoplasmic reticulum retention sequence (RDEL) and the Golgi complex in the cytotonic activity of Escherichia coli heat-labile enterotoxin. Mol. Microbiol. 1995; 16: 789-800.
23. Lencer WI, Constable C, Moe S et al. Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: Role of COOH-terminal KDEL. J. Cell Biol. 1995; 131: 951-62.
24. Sears CL, Kaper JB. Enteric bacterial toxins: Mechanism of action and linkage to intestinal secretion. Microbiol. Rev. 1996; 60: 167-215.
25. Levine MM, Kaper JB, Herrington D et al. Volunteer studies of deletion mutants of V. cholerae O1 prepared by recombinant techniques. Infect. Immun. 1988; 56: 161-7.
26. Lycke N, Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 1986; 59: 301-8.
27. Clements JD, Hartzog NM, Lyon FL. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 1988; 6: 269-77.
28. Elson CO, Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J. Immunol. 1984; 132: 2736-41.
29. Pierce NF, Cray WC. Determinants of the localization, magnitude, and duration of a specific IgA plasma cell response in enterically immunized rats. J. Immunol. 1982; 128: 1311-15.
30. Marinaro M, Staats HF, Hiroi T et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 1995; 155: 4621-9.
31. Xu-Amano J, Jackson RJ, Fujihashi K, Kiyono H, Staats HF, McGhee JR. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine 1993; 12: 903-11.
32. Xu-Amano J, Kiyono H, Jackson RJ et al. Helper T cell subsets for immunoglobulin A responses: Oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J. Exp. Med. 1993; 178: 1309-20.
33. Takahashi I, Marinaro M, Kiyono H et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile toxin. J. Infect. Dis. 1996; 173: 627-35.
34. Chen KS, Strober W. Cholera holotoxin and its B subunit enhance Peyer's patch B cell responses induced by orally administered influenza virus: Disproportionate cholera toxin enhancement of the IgA B cell response. Eur. J. Immunol. 1990; 20: 433-6.
35. Lebman DA, Fuhrman JA, Cebra JJ. Intraduodenal application of cholera holotoxin increases the potential of clones from Peyer's patch B cells of relevant and unrelated specificities to secrete IgG and IgA. Reg. Immunol. 1988; 1: 32-40.
36. Lycke N, Holmgren J. Adoptive transfer of gut mucosal antitoxin memory by isolated B cells 1 year after oral immunization with cholera toxin. Infect. Immun. 1989; 57: 1137-41.
37. Jertborn M, Svennerholm AM, Holmgren J. Immunological memory after immunization with oral cholera B subunit-whole-cell vaccine in Swedish volunteers. Vaccine 1994; 12: 1078-82.
38. Czerkinsky C, Svennerholm AM, Quiding M, Jonsson R, Holmgren J. Antibody-producing cells in peripheral blood and salivary glands after cholera vaccination in humans. Inject. Immun. 1991; 59: 996-1001.
39. Kozlowski PA, Chu-Uvin S, Neutra MR, Flanigan TR. Comparison of the oral, rectal and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect. Immun. 1997; 65: 1387-94.
40. Bergquist C, Johansson EL, Lagergård T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 1997; 65: 2676-84.
41. de Haan L, Verweij WR, Holtrop M, Agsteribbe E, Wilschut J. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: Role of the A subunit. Vaccine 1996; 14: 620-6.
42. de Haan L, Verweij WR, Feil IK et al. Mutants of the Escherichia coli heat-labile enterotoxin with reduced ADP-ribosylation activity or no activity retain the immunogenic properties of the native holotoxin. Infect. Immun. 1996; 64: 5413-16.
43. M1-binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology (in press).
44. M1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur. J. Immunol. (in press).
45. de Haan L, Holtrop M, Verweij WR, Agsteribbe E, Wilschut J. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. International Immunology (in press).
46. De Aizpurua HJ, Russell-Jones GJ. Oral vaccination: Identification of classes of proteins that provoke an immune response upon oral feeding. J. Exp. Med. 1988; 167: 440-51.
47. Nashar TO, Webb HM, Eaglestone S, Williams NA, Hirst TR. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: Receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc. Natl Acad. Sci. USA 1996; 93: 226-30.
48. Guidry JJ, Cardenas L, Chueng E, Clements JD. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect. Immun. 1997; 65: 4943-50.
49. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of V. cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur. J. Immunol. 1992; 22: 2277-81.
50. Douce G, Turcotte C, Cropley I et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as non-toxic, mucosal adjuvants. Proc. Natl Acad. Sci. USA 1995; 92: 1644-8.
51. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect. Immun. 1995; 63: 1617-23.
52. Di Tommaso A, Saletti G, Pizza M et al. Induction of antigen-specific antibodies in vaginal secretions by using a non-toxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect. Immun. 1996; 64: 974-9.
53. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect. Immun. 1997; 65: 2821-8.
54. Ghiara P, Rossi M, Marchetti M et al. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection. Infect. Immun. 1997; 65: 4996-5002.
55. Verweij WR, de Haan L, Holtrop M et al. Mucosal immuno-adjuvant activity of the recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine (in press).
56. de Haan L, Verweij WR, Holtrop M et al. Non-toxic variants of the Escherichia coli heat-labile enterotoxin as mucosal immunogens and adjuvants. STP Pharma. Sciences (in press).
57. Yamamoto S, Takeda Y, Yamamoto M et al. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrhoea-genicity but retain adjuvanticity. J. Exp. Med. 1997; 185: 1203-10.
58. Yamamoto S, Kiyono H, Yamamoto M et al. A non-toxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl Acad. Sci. USA 1997; 94: 5267-72.
59. Holmgren J, Lycke N, Czerkinsky C. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 1993; 11: 1179-84.
60. Peterson A, Hejtmancik DE, Markel DE, Craig JP, Kurosky A. Antigenic specificity of neutralizing antibody to cholera toxin. Infect. Immun. 1979; 24: 774-81.
61. Pizza M, Fontana MR, Giuliani MM et al. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit. J. Exp. Med. 1994; 180: 2147-53.
62. Fontana MR, Manetti R, Giannelli V et al. Construction of non-toxic derivatives of cholera toxin and characterization of the immunological response against the A subunit. Infect. Immun. 1995; 63: 2356-60.
63. Ågren LC, Ekman L, Löwenadler B, Lycke NY. Genetically engineered non-toxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A subunit. J. Immunol. 1997; 158: 3936-46.
64. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect. Immun. 1989; 57: 1072-7.
65. Katz JM, Lu X, Young SA, Galphin JC. Adjuvant activity of the heat-labile enterotoxin from enterotoxigenic Escherichia coli for oral administration of inactivated influenza virus vaccine. J. Infect. Dis. 1997; 175: 352-63.
66. Abraham E, Robinson A. Oral immunization with bacterial polysaccharide and adjuvant enhances antigen-specific pulmonary secretory antibody response and resistance to pneumonia. Vaccine 1991; 9: 757-64.
67. Liang X, Lamm ME, Nedrud JG. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J. Immunol. 1988; 141: 1495-501.
68. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR. Optimizing oral vaccines: Induction of systemic and mucosal B cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect. Immun. 1993; 61: 4272-9.
69. Rollwagen FM, Pacheco ND, Clements JD, Pavlovskis O, Rollins DM, Walker RI. Killed Campylobacter elicits immune response and protection when administered with an oral adjuvant. Vaccine 1993; 11: 1316-20.
70. Bourguin I, Chardés T, Bout D. Oral immunization with Toxoplasma gondii antigens in association with cholera toxin induces enhanced protective and cell-mediated immunity in C57BL/6 mice. Infect. Immun. 1993; 61: 2082-8.
71. Walsh EE. Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 1993; 11: 1135-8.
72. Pappo J, Thomas WD, Kabok Z, Taylor NS, Murphy JC, Fox JG. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect. Immun. 1995; 63: 1246-52.
73. Akhiani AA, Nilsson LA, Ouchterlony O. Effect of cholera toxin on vaccine-induced immunity and infection in murine Schistosomiasis mansoni. Infect. Immun. 1993; 61: 4919-24.
74. Debard N, Buzoni-Gatel D, Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect. Immun. 1996; 64: 2158-66.
75. Yamamoto M, McDaniel LS, Kawabata K et al. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection. Infect. Immun. 1997; 65: 640-4.
76. Elson CO, Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J. Immunol. 1984; 133: 2892-7.
77. Baqar S, Bougeois AL, Schultheiss PJ et al. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 1995; 13: 22-8.
78. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect. Immun. 1996; 64: 1272-83.
79. Vajdy M, Lycke N. Stimulation of antigen-specific T- and B-cell memory in local as well as systemic lymphoid tissues following oral immunization with cholera toxin adjuvant. Immunology 1993; 80: 197-203.
80. Clarke CJ, Wilson AD, Williams NA, Stokes CR. Mucosal priming of T lymphocyte response to fed protein antigens using cholera toxin as an adjuvant. Immunology 1991; 72: 323-8.
81. Hörnquist E, Lycke N. Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur. J. Immunol. 1993; 23: 2136-43.
82. Marinaro M, Boyaka PN, Finkelman FD et al. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 1997; 185: 415-27.
83. Vajdy M, Kosco-Vilbois MH, Kopf M, Köhler G, Lycke N. Impaired mucosal immune response in interleukin 4-targeted mice. J. Exp. Med. 1995; 181: 41-53.
84. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect. Immun. 1996; 64: 1516-25.
85. Tamura SI, Samegai Y, Kurata H, Nagamine T, Aizawa C, Kurata T. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 1988; 6: 409-15.
86. Wilson AD, Clarke CJ, Stokes CR. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet hemocyanin. Scand. J. Immunol. 1990; 31: 443-51.
87. Wu HY, Russell MW. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect. Immun. 1993; 61: 314-22.
88. Orr N, Arnon R, Rubin G, Cohen D, Bercovier H, Lowell GH. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines. Infect. Immun. 1994; 62: 5198-200.
89. Lee A, Chen M. Successful immunization against gastric infection with Helicobacter species: Use of cholera toxin B-subunit-whole-cell vaccine. Infect. Immun. 1994; 62: 3594-7.
90. Muller CP, Beauverger P, Schneider F, Jung G, Brons NHC. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus. J. Gen. Virol. 1995; 76: 1371-80.
91. Vadolas J, Davies JK, Wright PJ, Strugnell RA. Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur. J. Immunol. 1995; 25: 969-75.
92. Takase H, Murakami Y, Endo A, Ikeuchi T. Antibody responses in mice immunized orally against influenza virus. Vaccine 1996; 14: 1651-6.
93. Hazama M, Mayumi-Aono A, Miyazaki T, Hinuma S, Fujisawa Y. Intranasal immunization against herpes simplex virus by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat-labile enterotoxin and interleukin-2. Immunology 1993; 78: 643-9.
94. Tamura SI, Yamanaka A, Shimohara M et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 1994; 12: 419-26.
95. Tamura SI, Asanuma H, Tomita T et al. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine 1994; 12: 1083-9.